Patients | 103 (100.0) | 79 (100.0) | 24 (100.0) | – |
Age at Dlm initiation years | 34 (28–43) | 35 (30–43) | 31 (21–40) | 0.073 |
<18 years of age | 8 (8.8) | 3 (3.8) | 5 (20.8) | 0.016 |
Male | 63 (61.2) | 47 (59.5) | 16 (66.7) | 0.53 |
Body mass index at Dlm initiation kg·m−2 | 20.4 (17.7–23.6)+ | 20.4 (17.8–23.6)§ | 20.2 (17.6–23.7)ƒ | 0.92 |
QTcF at Dlm initiation ms | 412.8 (394.0–433.0)## | 412.6 (394.0–436.0) | 414.0 (394.0–427.0)## | 0.77 |
Albumin at Dlm initiation g·L−1 | 35.0 (29.0–39.0)¶¶ | 35.0 (29.0–38.0)++ | 38.0 (29.5–40.0)§§ | 0.087 |
Diabetic | 4 (3.9) | 1 (1.3) | 3 (12.5) | 0.039 |
CD4 count at Dlm initiation cells·mm−3 | | 141.0 (61.0–252.0)ƒƒ | | – |
Antiretroviral therapy at Dlm initiation | | 72 (91.1) | | – |
RR-TB disease classification | | | | |
Presumed RR-TB# | 1 (1.0) | 0 (0.0) | 1 (4.2) | – |
GeneXpert unconfirmed¶ | 3 (2.9) | 2 (2.5) | 1 (4.2) | – |
Rifampicin mono-resistant TB | 21 (20.4) | 18 (22.8) | 3 (12.5) | – |
Multidrug-resistant TB | 41 (39.8) | 36 (45.5) | 5 (20.8) | – |
Pre-XDR-TB injectable | 5 (4.8) | 4 (5.1) | 1 (4.2) | – |
Pre-XDR-TB fluoroquinolone | 15 (14.6) | 7 (8.9) | 8 (33.3) | – |
XDR-TB | 17 (16.5) | 12 (15.2) | 5 (20.8) | 0.014 |
Previous TB treatment history | | | | |
None | 44 (42.7) | 34 (43.0) | 10 (41.6) | – |
First-line | 43 (41.8) | 36 (45.6) | 7 (29.2) | – |
Second-line | 16 (15.5) | 9 (11.4) | 7 (29.2) | 0.085 |
Disease site | | | | |
Pulmonary | 97 (94.2) | 74 (93.7) | 23 (95.8) | – |
Extrapulmonary | 5 (4.8) | 4 (5.0) | 1 (4.2) | – |
Both | 1 (1.0) | 1 (1.3) | 0 (0.0) | 1.0 |
Culture status at Dlm initiation | | | | |
Negative | 42 (40.8) | 35 (44.3) | 7 (29.2) | – |
Positive | 58 (56.3) | 42 (53.2) | 16 (66.7) | – |
Contaminated | 2 (1.9) | 2 (2.5) | 0 (0.0) | – |
Not done | 1 (1.0) | 0 (0.0) | 1 (4.1) | 0.16 |
Indication for Dlm | | | | |
Intolerance | 58 (56.3) | 48 (60.8) | 10 (41.7) | – |
Limited therapeutic options | 38 (36.9) | 27 (34.2) | 11 (45.8) | – |
Treatment failure | 7 (6.8) | 4 (5.0) | 3 (12.5) | 0.16 |
Time from RR-TB treatment to Dlm initiation months | 1.5 (0.8–3.2) | 1.5 (0.8–3.2) | 1.7 (1.2–4.7) | 0.35 |
Received >6 months of Dlm | 54 (52.4) | 39 (49.4) | 15 (62.5) | 0.26 |